In the ApcMin/+ intestinal cancer model, injection of anti‐IL‐36γ significantly improved the survival of ApcMin/+ mice and inhibited the tumorigenesis and tumor development in the colon and the small intestine compared to injection of the control IgG (Figure S8A–C, Supporting Information). This evidence concerns the gene IL36G and neoplasm.